Semaglutide, a GLP-1 receptor agonist, reaches steady-state blood levels after four to five weeks of once-weekly dosing, with a half-life of approximately one week
Semaglutide is also marketed as Wegovy, for treatment of obesity
Inject Semaglutide once per week as directed by your prescribing provider
Safety Considerations When Using Allulose Allulose is generally recognised as well-tolerated when consumed in moderate amounts, though several safety considerations warrant attention
Your liver has no GLP-1 or GIP receptors
Dosing is structured around injection frequency, timing relative to meals and sleep cycles, and whether the peptide is being administered alone or stacked with other growth hormone secretagogues like CJC-1295